Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC

EP. 11: Evaluating Pemetrexed Exposure in FLAURA2: Key Findings and Treatment Implications

May 2nd 2025

Panelists discuss how the FLAURA2 pemetrexed exposure subanalysis showed that patients could benefit from the regimen even if they didn't complete the full maintenance period as prescribed in the trial.

EP. 12: 56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen

May 2nd 2025

Panelists discuss how a 56-year-old patient with high-risk disease features was successfully treated with osimertinib plus chemotherapy, achieving excellent response before eventually discontinuing pemetrexed maintenance while continuing osimertinib.

EP. 13: 45-Year-Old Never-Smoker with Advanced EGFR-Mutant NSCLC and CNS Metastases Treated with the MARIPOSA Regimen

May 2nd 2025

Panelists discuss how a 45-year-old anxious patient who refused chemotherapy was successfully treated with amivantamab plus lazertinib along with prophylactic management strategies for potential adverse effects.

EP. 14: Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC

May 2nd 2025

Panelists discuss how despite recent advances in first-line treatments, unmet needs remain. These include better personalized care, community education, understanding resistance mechanisms, central nervous system (CNS) metastases management, and development of novel therapies such as antibody-drug conjugates.